{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:21Z","timestamp":1792839741516,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018336","name":"National Institute for Health Research Health Protection Research Unit","doi-asserted-by":"publisher","award":["NIHR200911"],"award-info":[{"award-number":["NIHR200911"]}],"id":[{"id":"10.13039\/100018336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jinf.2025.106465","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:55:56Z","timestamp":1741143356000},"page":"106465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Direct-acting antiviral treatment outcomes in people infected with endemic compared to epidemic hepatitis C virus subtypes in England"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6453-0129","authenticated-orcid":false,"given":"Laura T.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7186-2482","authenticated-orcid":false,"given":"Daniel","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8156-0146","authenticated-orcid":false,"given":"Ruth","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5173-2760","authenticated-orcid":false,"given":"Caroline A.","family":"Sabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-9679","authenticated-orcid":false,"given":"Jean L.","family":"Mbisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jinf.2025.106465_bib1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jinf.2025.106465_bib2","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jinf.2025.106465_bib3","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2025.106465_bib4","series-title":"Hepatitis C: Epidemiology, Prevention and Elimination: Volume 1","first-page":"55","article-title":"Classification, genetic diversity and global distribution of hepatitis C virus (HCV) genotypes and subtypes","author":"Paraskevis","year":"2021"},{"key":"10.1016\/j.jinf.2025.106465_bib5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"O.G. Pybus, et al., Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jinf.2025.106465_bib6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2021.04.045","article-title":"Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens","volume":"75","author":"Shah","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jinf.2025.106465_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.meegid.2004.08.001","article-title":"The hepatitis C virus epidemic among injecting drug users","volume":"5","author":"Pybus","year":"2005","journal-title":"Infect Genet Evol"},{"issue":"6","key":"10.1016\/j.jinf.2025.106465_bib8","doi-asserted-by":"crossref","first-page":"e1254","DOI":"10.1093\/infdis\/jiae253","article-title":"Identification of 2 Novel Subtypes of Hepatitis C Virus Genotype 8 and a Potential New Genotype Successfully Treated With Direct Acting Antivirals","volume":"230","author":"Mbisa","year":"2024","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2025.106465_bib9","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/infdis\/jiz155","article-title":"Hepatitis C Virus Genotype 8 Infection-Successful Treatment With Sofosbuvir\/Velpatasvir","volume":"220","author":"Douglas","year":"2019","journal-title":"Infect Dis"},{"issue":"Pt 2","key":"10.1016\/j.jinf.2025.106465_bib10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1099\/0022-1317-78-2-321","article-title":"PL Yap et al., The origin of hepatitis C virus genotypes","volume":"78","author":"Smith","year":"1997","journal-title":"J Gen Virol"},{"issue":"6","key":"10.1016\/j.jinf.2025.106465_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/infdis\/jiab110","article-title":"Real-world outcomes of DAA treatment and retreatment in UK-based patients infected with HCV genotypes\/subtypes endemic in Africa","volume":"226","author":"Aranday-Cortes","year":"2021","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.jinf.2025.106465_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.07.025","article-title":"Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: implications for global elimination of hepatitis C","volume":"71","author":"Childs","year":"2019","journal-title":"J Hepatol"},{"issue":"Supplement 1","key":"10.1016\/j.jinf.2025.106465_bib13","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0168-8278(18)30320-9","article-title":"Direct-acting antiviral treatment in sub-Saharan Africa: a prospective trial of Ledipasvir\/Sofosbuvir for chronic hepatitis C infection in Rwanda (the SHARED study)","volume":"68","author":"Gupta","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jinf.2025.106465_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab006","article-title":"Direct-acting antiviral treatment for hepatitis C genotypes uncommon in high-income countries: a Dutch Nationwide Cohort Study","volume":"8","author":"Isfordink","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2025.106465_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","article-title":"Sofosbuvir\u2013velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial","volume":"4","author":"Wei","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.jinf.2025.106465_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008209","article-title":"Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice","volume":"4","author":"Chevaliez","year":"2009","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jinf.2025.106465_bib17","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/jvh.13322","article-title":"Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection","volume":"27","author":"Dietz","year":"2020","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.jinf.2025.106465_bib18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/hep.30225","article-title":"Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r","volume":"69","author":"Fourati","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jinf.2025.106465_bib19","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.29837","article-title":"Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors","volume":"69","author":"Smith","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jinf.2025.106465_bib20","article-title":"Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients","volume":"6","author":"Dietz","year":"2024","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.jinf.2025.106465_bib21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/HEP.0000000000000379","article-title":"Virological characterization of treatment failures and retreatment outcomes in patients infected with \u201cunusual\u201d HCV genotype 1 subtypes","volume":"78","author":"Vo-Quang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jinf.2025.106465_bib22","doi-asserted-by":"crossref","first-page":"576572","DOI":"10.3389\/fmicb.2020.576572","article-title":"Technical validation of a hepatitis C virus whole genome sequencing assay for detection of genotype and antiviral resistance in the clinical pathway","volume":"11","author":"Manso","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jinf.2025.106465_bib23","unstructured":"Harris HE, Costella A, Mandal S, contributors. Hepatitis C treatment monitoring in England: Content, completeness and preliminary findings from the Hepatitis C patient registry and treatment outcome system; 2018. November 2018. Accessed 14\/03\/24. https:\/\/assets.publishing.service.gov.uk\/media\/5bedb331e5274a084abc8474\/HCV_treatment_monitoring_report_2018.pdf."},{"issue":"3","key":"10.1016\/j.jinf.2025.106465_bib24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cmi.2021.06.042","article-title":"Clinical evaluation of a hepatitis C virus whole-genome sequencing pipeline for genotyping and resistance testing","volume":"28","author":"Bradshaw","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.jinf.2025.106465_bib25","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/v11040323","article-title":"Interpreting viral deep sequencing data with GLUE","volume":"11","author":"Singer","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.jinf.2025.106465_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist Updates"},{"key":"10.1016\/j.jinf.2025.106465_bib27","unstructured":"R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2021. Accessed 18\/05\/24 \u3008https:\/\/www.R-project.org\/\u3009."},{"issue":"2","key":"10.1016\/j.jinf.2025.106465_bib28","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1093\/ije\/dyaa213","article-title":"Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations","volume":"50","author":"Tennant","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"9","key":"10.1016\/j.jinf.2025.106465_bib29","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S2468-1253(20)30086-8","article-title":"Glecaprevir\u2013pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies\u2014a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)","volume":"5","author":"Wei","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jinf.2025.106465_bib30","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","author":"Blach","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jinf.2025.106465_bib31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S2468-1253(21)00398-8","article-title":"Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial","volume":"7","author":"Kateera","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jinf.2025.106465_bib32","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/liv.14535","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients with HCV genotype 5\/6: an integrated analysis of phase 2\/3 studies","volume":"40","author":"Yao","year":"2020","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.jinf.2025.106465_bib33","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1136\/gutjnl-2024-332177","article-title":"Unusual\u2019 HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment","volume":"73","author":"Vo-Quang","year":"2024","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jinf.2025.106465_bib34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrgastro.2013.179","article-title":"HCV transmission in industrialized countries and resource-constrained areas","volume":"11","author":"Thursz","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jinf.2025.106465_bib35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/jvh.13757","article-title":"Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination","volume":"30","author":"Bryce","year":"2023","journal-title":"J Viral Hepat"},{"issue":"1","key":"10.1016\/j.jinf.2025.106465_bib36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10620-022-07483-y","article-title":"Liver disease and poor adherence limit hepatitis C cure: a real-world Australian Treatment Cohort","volume":"68","author":"Clark","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.jinf.2025.106465_bib37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/jvh.13901","article-title":"Sex-related difference analyses of efficacy and safety in clinical trials of direct-acting antivirals to treat chronic HCV genotype 1 and 3 infections","volume":"31","author":"Zhou","year":"2024","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.jinf.2025.106465_bib38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.clinre.2011.01.005","article-title":"HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C","volume":"35","author":"Costa","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"9055","key":"10.1016\/j.jinf.2025.106465_bib39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jinf.2025.106465_bib40","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.idc.2017.07.014","article-title":"Hepatitis C virus infection in the older patient","volume":"31","author":"Reid","year":"2017","journal-title":"Infect Dis Clin North Am"},{"issue":"5","key":"10.1016\/j.jinf.2025.106465_bib41","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jhep.2017.01.007","article-title":"NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome","volume":"66","author":"Zeuzem","year":"2017","journal-title":"J Hepatol"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325000593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445325000593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:32:13Z","timestamp":1762248733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445325000593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0163445325000593"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106465","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct-acting antiviral treatment outcomes in people infected with endemic compared to epidemic hepatitis C virus subtypes in England","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2025.106465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106465"}}